<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/7A548FB1-2906-495F-9C5E-59F0EE55EF4A"><gtr:id>7A548FB1-2906-495F-9C5E-59F0EE55EF4A</gtr:id><gtr:name>Mathematical, Physical &amp; Life Sciences Division</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/1354C618-9C7F-4E90-97AE-2A04B4C8536D"><gtr:id>1354C618-9C7F-4E90-97AE-2A04B4C8536D</gtr:id><gtr:name>Cancer Research UK (CRUK)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/7D129DA2-C185-4D12-AEB3-9AAB8A63179E"><gtr:id>7D129DA2-C185-4D12-AEB3-9AAB8A63179E</gtr:id><gtr:name>Biocenter Oulu</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Obstetrics and Gynaecology</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/7A548FB1-2906-495F-9C5E-59F0EE55EF4A"><gtr:id>7A548FB1-2906-495F-9C5E-59F0EE55EF4A</gtr:id><gtr:name>Mathematical, Physical &amp; Life Sciences Division</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/1354C618-9C7F-4E90-97AE-2A04B4C8536D"><gtr:id>1354C618-9C7F-4E90-97AE-2A04B4C8536D</gtr:id><gtr:name>Cancer Research UK (CRUK)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/7D129DA2-C185-4D12-AEB3-9AAB8A63179E"><gtr:id>7D129DA2-C185-4D12-AEB3-9AAB8A63179E</gtr:id><gtr:name>Biocenter Oulu</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/806E292E-71D4-449E-80EA-E44137F8B1C0"><gtr:id>806E292E-71D4-449E-80EA-E44137F8B1C0</gtr:id><gtr:firstName>Karl</gtr:firstName><gtr:surname>Morten</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/91681F06-FB0C-421D-A8E0-A8D14BDA464F"><gtr:id>91681F06-FB0C-421D-A8E0-A8D14BDA464F</gtr:id><gtr:firstName>Joanna</gtr:firstName><gtr:surname>Poulton</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0500695"><gtr:id>1E43401C-E7B8-4EB2-B5B7-B830EA95DE4F</gtr:id><gtr:title>The importance of mitochondrial oxidative stress on beta cells in type II diabetes</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0500695</gtr:grantReference><gtr:abstractText>We aim to study natural mechanisms that protect people from diabetes in the beta cells that make insulin. This will help design treatments that may prevent people from developing diabetes. 
Mitochondria are small parts of cells that generate energy. They also generate damaging by-products called free radicals, that are inactivated by an enzyme called superoxide dismutase (SOD). Mitochondria have their own DNA, mtDNA, a blueprint for proteins needed to make energy. Variations in mtDNA make diabetes more likely by reducing the energy supplied to the beta cells. We will use molecular techniques to lower SOD levels in cultured beta cells and determine whether this increases levels of the damaging free radicals. We will determine whether these changes decrease insulin production, as this would make diabetes likely. 
Once beta cells are damaged they cannot readily be regenerated and this causes insulin deficiency. Our results may suggest novel treatments with drugs that counteract free radicals to prevent failure of the beta cells. Finding a treatment to prevent this damage would change how we treat patients whose mtDNA predisposes them to diabetes. This includes 140,000 diabetics in the UK and ~95% of people in Polynesia, where diabetes is very common.</gtr:abstractText><gtr:technicalSummary>Beta-cell dysfunction is an important component of type 2 diabetes (T2D) that is increasingly implicated early in pathogenesis. Age associated mitochondrial oxidative stress has been implicated in the development of a number of condtions including T2D.

Our research objective is to investigate the effect of mitochondrial oxidative stress on cellular pathways associated with insulin secretion (B-cells). We will investigate the effects of mitochondrial reactive oxygen species (ROS), which may be increased as the result of respiratory chain dysfunction and/or impaired antioxidant defence systems, on mitochondrial function and insulin secretion in beta cells. We will test the hypothesis that mitochondrial ROS damage mitochondrial protein and mtDNA in B-cells and hence contribute to the pathogenesis of type II diabetes. 

We have recently shown that 1) mtDNA mutations may be associated with increased ROS production and respiratory chain dysfunction and 2) high ROS levels in the mitochondrial superoxide dismutase (SOD2) knockout mouse are associated with major increases in the phosphorylation state of proteins associated with disease pathology (Morten unpublished). Hence, oxidative stress may impair both mitochondrial function and cell signaling in the B-cell, with a major impact on both insulin release. 

In this proposal we will:-
1)Increase levels of ROS in immortalised mouse beta cells by targeting SOD2 with RNA interference (shRNA technology) to decrease cellular antioxidant defences. We will confirm specificity at the level of RNA and protein expression, and use ROS sensitive dyes to demonstrate increased ROS production .
2)Investigate the relationship between mitochondrial ROS and mtDNA damage in cultured mouse beta-cells and ES cells with mildly reduced Sod2 expression. 
3)Use real time PCR, and fluorescence imaging to assess the effects of ROS on mtDNA copy number. 
4)Determine the effect of elevated beta-cell ROS on mitochondrial function and mitochondrial protein turnover using a combination of sensitive assays which KM has developed for ROS and respiratory complexes enzymology, 2 D protein turnover analysis and sucrose gradient fractionation.
5)Determine the effect of mitochondrial ROS on B-cell insulin secretion and assess interactions with fatty acid loading. Total and secreted insulin will be measured by radioimmunoassay. ATP and calcium levels will be measured by fluroimetry and fluroscent techniques. 

These studies will provide the groundwork to generate a mouse model of mitochondrial oxidative stress with which to investigate type II diabetes. Understanding the effect of ROS on insulin secretion will suggest novel therapies for preventing beta cell failure, such as antioxidant therapy, which can be tested in this model.</gtr:technicalSummary><gtr:fund><gtr:end>2008-12-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2006-01-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>259652</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cancer Research UK (CRUK)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Professor Adrian Harris</gtr:description><gtr:id>A9B3D5C0-647A-453E-970A-313CB45333F9</gtr:id><gtr:impact>Multidisciplinary (findings will be applied to clinical samples)
Collaborative grant application KJM</gtr:impact><gtr:partnerContribution>New project ongoing</gtr:partnerContribution><gtr:piContribution>KJM does metabolic analysis</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Mathematical, Physical &amp; Life Sciences Division</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Engineering Science</gtr:department><gtr:description>Nanomedicine collaboration with the Engineering and Materials Sciences</gtr:description><gtr:id>41DF5F73-D530-4786-9122-228676B27E8D</gtr:id><gtr:impact>This project has recieved funding from several sources: 1)SEEDA funded research grant to fund a SEEDA Professorial fellow to work with Dr Karl Morten and Prof's Phil Legrani and Pete Dobson on the microfluidic separation of biological Nanoparticles (&amp;pound;150k). 2)University of Oxford John Fell Fund, Pump priming grant. Microfluidic Separation of Biological Nanoparticles. Dr Karl Morten with Professor Ligrani (&amp;pound;90k). 3)University of Oxford Seed fund. Pump priming grant. Microfluidic Separation of Biological Nanoparticles. Dr Karl Morten with Prof Ligrani (&amp;pound;35k). 4)Camila Samuel Fund (Sir Ronald Grierson). Start up grant 6 months. Mitochondrial therapeutics, and specific vascular delivery using nanotechnology for novel cancer treatments. Dr Karl Morten with Miss E Rapa (&amp;pound;27k). 5) Investigation of aptamer drug delivery strategies for Neuroblastoma. Funded by Dr Chris Mitchells charitable funds Oct 2009- Sept 2010. 6) Separation of aptamer coupled Nanoparticles. Msc research project (Miss Alicja Bulsiewicz &amp;amp; Dr Alex Lubansky/ Professor Richard Darton, Dept of Engineering Science Nov 2009- Oct-2011).</gtr:impact><gtr:partnerContribution>Allowed us to establish a multidisciplinary collaboration</gtr:partnerContribution><gtr:piContribution>Karl Morten has set up and established a series of collaborations with the Engineering(Drs Alex Lubansky, Helen Townley &amp;amp; Professor Richard Darton) and Material Sciences (Professor Peter Dobson)</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Mitochondrial Biology Unit</gtr:department><gtr:description>Collaboration with Mitochondrial Biology Unit</gtr:description><gtr:id>F66716F7-FC03-496D-B6D4-7BBDD4229F22</gtr:id><gtr:impact>We co-chaired an international workshop (163rd ENMC International Workshop: Nucleoid and nucleotide biology in syndromes of mitochondrial DNA depletion myopathy. 12-14 December 2008, Naarden, The Netherlands) resulting in 2 publications. Cross-ferlisation of ideas result in a PLOS-genetics paper in 2010 and a Nucleic Acids Research paper in 2009.</gtr:impact><gtr:partnerContribution>Ian has provided reagents advice and expertise for many years</gtr:partnerContribution><gtr:piContribution>I provide him with ideas and patient materials.</gtr:piContribution><gtr:sector>Public</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Nuffield Department of Clinical Medicine</gtr:department><gtr:description>Collaboration with Dr K Simon</gtr:description><gtr:id>E6F93FC5-3DD6-4592-B568-2910E02B1D96</gtr:id><gtr:impact>Submitted publications
Abstracts accepted for Biochemical Society meeting, Mitochondrial Dynamics meeting, EUROMIT</gtr:impact><gtr:partnerContribution>Access to ImageStream technology and Expertise
Wellcome Trust Funding</gtr:partnerContribution><gtr:piContribution>Research activity</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Epidemiology Unit</gtr:department><gtr:description>Collaboration with MRC Epidemiology Unit</gtr:description><gtr:id>B2033AE8-2524-446A-A18F-2CE8D8E6A565</gtr:id><gtr:impact>We have had the meta-analysis paper in draft for 2 years, and are now carrying out the laboratory side of the study (large case-control study of type 2 diabetics).</gtr:impact><gtr:partnerContribution>We collaborated with a data review and meta-analysis confirming my finding that a common mtDNA variant is a risk factor for type 2 diabetes. We are now screening a large case-control study to determine whether we can replicate our finding that a mtDNA variant that I characterised is significantly enriched in diabetics compared to matched controls. If confirmed my finding will link 2 large MRC groups located on the Addenbrookes campus in investigating type 2 diabetes. This is because the variant that I identified maps precisely to a novel origin of replication (see collaboration with Dr Ian Holt, Mitochondrial Biology Unit).</gtr:partnerContribution><gtr:piContribution>I conceived this project and made the initial findings. Dr Holt then mapped a novel origin of mtDNA replication precisely to the location of the variant. I helped Dr Sims set up the screening technique by providing the positive controls of the sequence variants and advising on the genetic diversity and its interpretation.</gtr:piContribution><gtr:sector>Public</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's College London (KCL)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Medicine KCL</gtr:department><gtr:description>Collaboration with Kings College London</gtr:description><gtr:id>F750CE8D-8322-494F-8F53-D6479941B2F8</gtr:id><gtr:impact>We plan to write a collaborative paper</gtr:impact><gtr:partnerContribution>We plan to discuss the analysis of Toby's data in respect of OPA1 and PARP and write a collaborative paper</gtr:partnerContribution><gtr:piContribution>Our current work focusses on mitochondrial turnover which will inform the mechanism of the associations Dr Toby Andrew is studying.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Biocenter Oulu</gtr:collaboratingOrganisation><gtr:country>Finland, Republic of</gtr:country><gtr:department>Department of Paediatric Neurology</gtr:department><gtr:description>Investigation of patients with mitochondrial disease</gtr:description><gtr:id>0B489F56-2EAF-44B9-99CA-7EF46C177F05</gtr:id><gtr:impact>Paper submitted to Epilepsia
Prospective study of POLG1 mutations presenting in children with intractable epilepsy-prevalence and clinical features
J Uusimaa, V Gowda, A McShane, C Smith, J Evans, A Shrier, M Narasimhan, A O'Rourke, Y Rajabally, F Cowan, C Fratter, J Poulton
Paper in draft for submission to J Med Genet
Benign Cytochrome Oxidase Deficiency or Reversible Infantile Respiratory Chain Deficiency: Evidence for genetic heterogeneity
Johanna Uusimaa, Heinz Jungbluth, G Crisponi, Lucy Feng, Massimo Zeviani, Imelda Hughes, Eileen Treacy, Jacqueline Birks, Caroline Sewry, Francesco Muntoni, and Joanna Poulton</gtr:impact><gtr:partnerContribution>JP flew to Oulu for collaborative meeting which enabled discussions with several other groups</gtr:partnerContribution><gtr:piContribution>JP collected the original cohort of patients, conceived the first proposal which was funded by The Sigrid Juselius Foundation, Finland (Co-applicant on Senior Research Fellowship for Dr J Uusimaa) 50,000 Eur and The Paediatric Foundation, Finlandand 20,000 Eur. JP and KM both co-authored the current application (Academy of Finland) on which both are collaborators.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Seminar to the Oxford Islet transplantation unit on mitochondrial function and beta cell failure</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>5D1DBB47-0A81-45BB-9237-793DA03459AF</gtr:id><gtr:impact>Seminar/discussion led to a series of collaborations with Mr Paul Johnson and Prof Patrik Rorsmann. This includes (i) new approaches to isolate islets for transplantation (collaboration with Engineering), (ii) investigating the role of the mtDNA 16189 diabetes susceptibility gene on islet function. This is a collaboration with a Swedish Group ( Dr Erik Renstrom), we have recently obtained ehtics to allow this collaboration to start

We are currently looking for funding for the islet separation work.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Sydney</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>882B92D8-58BC-4345-A35B-C30A9C9CE752</gtr:id><gtr:impact>Invited to give 60 min seminar to clinical scientists

Collaborative grant application to Wellcome Trust</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Seminar on the role of Mitochondrial ROS in disease to Oxford Hypoxia group</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>711D9D04-1D67-451B-8F9E-FB319AB34068</gtr:id><gtr:impact>Seminar to the Oxford goups has resulted in a series of discussions about future collaborations in the areas of Heart failure and novel treatments for Cancer.

Collaborations</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Nottingham</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>41A2AD5A-A38F-4E0E-9CC8-5FD34BA0A90B</gtr:id><gtr:impact>Invited seminar speaker, Paediatric dept, Nottingham

Collaboration</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>CGS</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>1DFDCB78-D15B-4637-AF9B-7C9477EBA3DD</gtr:id><gtr:impact>JP Invited 30 minute talk

Increased (i) queries regarding patients and advances (including the diagnostic approach we set up as a result of findings in my MRC CEG) and (ii) referrals to our NCG funded diagnostic service</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2008,2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Gordon conference</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>67FD5ED0-25E0-4C8F-A3EF-ABE067CE00AB</gtr:id><gtr:impact>2 poster presentations

Collaborations</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2006</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>St Marys</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>A4605384-56BB-4DCA-A851-D412E74D486E</gtr:id><gtr:impact>Talk in symposium at St Marys

Increased (i) queries regarding patients and advances (including the diagnostic approach we set up as a result of findings in my MRC CEG) and (ii) referrals to our NCG funded diagnostic service (iii)Collaboration discussions</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ENMC</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>8AF54363-8B6D-45D2-A742-445C4FF0C450</gtr:id><gtr:impact>Chairing International workshop, co-chaired with IJ Holt (MRC Cambridge). Wrote meeting reports (professional and lay) that appear on web, 2 publications arose

My report of the meeting has appeared in Neuromuscular Disorders and a collaborative paper that was generated in BBA</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BPNA</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>076F1647-EEE4-4440-9632-C432CD3E1CC3</gtr:id><gtr:impact>Plenary talk

Increased patient referrals</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2007,2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>CLIMB Lecture</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>3BC965F8-F20B-4100-8EDD-AF3B57243699</gtr:id><gtr:impact>JP invited to give an illustrated talk to families of mitochondrial patients for 40 minutes

Personal feedback from grateful families and commendation by chief exec of CLIMB as well as chairperson. Report to appear in organisation literature.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>251826</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust project grant</gtr:description><gtr:end>2014-07-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:id>B22D561B-98BA-4D61-BF57-673A7B2B6549</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>90000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Williams Fund</gtr:department><gtr:description>Williams Fund (Nanotherapeutics and cancer)</gtr:description><gtr:end>2013-09-02</gtr:end><gtr:fundingOrg>Oxford Radcliffe Hospitals NHS Trust</gtr:fundingOrg><gtr:id>2CC38002-E971-4B97-98B3-0CD254C7CCF8</gtr:id><gtr:sector>Hospitals</gtr:sector><gtr:start>2010-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>14000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>newlife</gtr:description><gtr:end>2012-05-02</gtr:end><gtr:fundingOrg>Newlife</gtr:fundingOrg><gtr:id>AE02CFD4-5AB3-4BFC-A3FD-3CD300B88632</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>60000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>NIHR Oxford Biomedical Research Centre</gtr:department><gtr:description>BRC Clinical Fellowship</gtr:description><gtr:end>2011-09-02</gtr:end><gtr:fundingOrg>Oxford University Hospitals NHS Trust</gtr:fundingOrg><gtr:id>DFCF945A-C87F-4BEB-8F8B-5BADCB84F779</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2010-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>120000</gtr:amountPounds><gtr:country>Finland, Republic of</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Academy of Finland (JP and KM are collaborating with a paeditric neurologist (JU who is the PI)/Finish Paediatric association</gtr:description><gtr:end>2013-12-02</gtr:end><gtr:fundingOrg>Finnish Medical Association</gtr:fundingOrg><gtr:id>4C0955D3-0ED0-4505-80AE-C38ACD6F7EB5</gtr:id><gtr:sector>Learned Society</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>10000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Medical Research Fund University of Oxford</gtr:description><gtr:end>2010-08-02</gtr:end><gtr:fundingOrg>University of Oxford</gtr:fundingOrg><gtr:id>663090F4-D58D-4321-879E-4E894891D924</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>7000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>The John Fell Fund</gtr:department><gtr:description>John Fell Small Award scheme</gtr:description><gtr:end>2011-01-02</gtr:end><gtr:fundingOrg>University of Oxford</gtr:fundingOrg><gtr:id>A22E84E4-97C0-4BFF-98D0-57A15A5F0BD6</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-07-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Invited to give 2 talks to HFEA committees</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>A9DD2548-8F80-445F-AE4D-C7F5EE71F851</gtr:id><gtr:impact>I suggested that HFEA should allow the Newcastle Mitochondrial research group working on nuclear transfer as a treatment for mitochondrial diseases should now be permitted to perform experiments on healthy single cell embryos rather than just abnormal ones.</gtr:impact><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>I am a member of the Royal Society stem cell consultation group</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>EC789035-2FEB-4B9F-99F7-4BE42EAE981B</gtr:id><gtr:impact>This consultation group submits evidence to governmental committees.; Royal Society report 2008</gtr:impact><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Cabinet office review</gtr:description><gtr:geographicReach>UK</gtr:geographicReach><gtr:id>F9980BFC-F1DF-487E-A92B-74EFEA1BE816</gtr:id><gtr:impact>Review of confidentiality of Records (K Lidbetter, Grade 6 Cabinet office)</gtr:impact><gtr:type>Participation in a national consultation</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Submissions to the HFEA open consultation on new techniques to prevent transmission of serious mitochondrial disease</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>9D3FC61E-9210-4EA4-AD5B-A53B5219F3B1</gtr:id><gtr:impact>Our collaborative paper (with Drs Joerg Burgstaller and Iain Johnston) on mitochondrial DNA segregation suggests that an additional restriction on the practice of mitochondrial donation for preventing mtDNA disease. We made a presentation to the review, suggesting that there should be an acceptably close mitochondrial genetic distance between donors of permitted embryos and of permitted eggs. When two mtDNA haplotypes are present in a cell (mtDNA heteroplasmy), it is usually assumed that segregation (the proliferation of one haplotype over another) is negligible and best explained by random drift. An intensively studied mouse model showing tissue-specific mtDNA segregation is currently seen as an exception to this assumption. However, existing studies of mtDNA dynamics have focused on laboratory mouse strains with very limited genetic diversity, thus ignoring the fact that genetic differences between haplotypes may lead to proliferative differences. We have data showing that in the mouse, segregation between two mtDNA haplotypes is the rule rather than the exception and strongly depends on the genetic distance. Segregation is much less when mitochondrial haplotypes are closely related than when they are diverse. The dataset on which this is based is substantially larger than in any previous such studies. Hence, the mtDNA of the permitted embryo might increase to disease-causing levels in later generations. We cannot exclude the possibility that there might be segregation to significant levels during development in foetuses developing from embryos generated by nuclear transfer. The risk would be substantially reduced by matching the mtDNA haplotype of donors.

These data were quoted in the HFEA report on the consultation.</gtr:impact><gtr:type>Citation in other policy documents</gtr:type><gtr:url>http://www.hfea.gov.uk/docs/Third_Mitochondrial_replacement_scientific_review.pdf</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>HFEA Review of the effectiveness and safety of methods to avoid mitochondria disease</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>5FD374C6-87FF-4E6C-85A2-E0383B39D4F7</gtr:id><gtr:impact>Invited to give evidence at Human Fertilisation and Embryology Authority (HFEA) review, which attracted international speakers (US and Netherlands). I was cited in the policy document arising from this.</gtr:impact><gtr:type>Citation in other policy documents</gtr:type><gtr:url>http://www.hfea.gov.uk/docs/2011-04-18_Mitochondria_review_-_final_report.PDF</gtr:url></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Cell line with DS red targeted to mitochondria for studying mitophagy</gtr:description><gtr:id>9C5844A6-61F8-4113-81DF-C28DCC390501</gtr:id><gtr:impact>Biochemical society meeting oral presentation</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>RedMIT mefs</gtr:title><gtr:type>Cell line</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>The reader allows us to set up experiments where we change oxygen conditions i.e modelling ischaemia reperfsuion injury. The experiements are run in real time and we are developing assays to monitor mitochondrial function and reactive oxygen species generation through out the experiment.</gtr:description><gtr:id>D6EF0722-5508-4090-BDDA-7DD5B261DD68</gtr:id><gtr:impact>We can measure oxygen consumption in a 96 plate format. Our current work looks at oxygen consumption from whole islets, INS-1 (insulinoma) cells and a whole range of cell lines. By scalling down the process further we hope to look at mitochondria isolated from small part areas of the brain</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Purchase of oxygen control plate reader from BMG labtech</gtr:title><gtr:type>Improvements to research infrastructure</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>In collaboration with Dr Paul Johnson &amp;amp; Dr Neil Waker at OCDEM we have been collecting human islets from individuals donating their islets for research. This mainly consists of control individuals but also includes several diabetic samples</gtr:description><gtr:id>D22FC26F-6A42-44F3-A219-1033D3D68201</gtr:id><gtr:impact>We have shown a link between reduced levels of mtDNA and high BMI.</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Collection of DNA from 30 human islets</gtr:title><gtr:type>Database/Collection of Data/Biological Samples</gtr:type><gtr:yearFirstProvided>2008</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Developing ImageStream (fluorescence mitoscopy combined with cytometry in a single platfrom) to quantify mitophagy</gtr:description><gtr:id>BB877301-737D-411D-9048-34C43E7CE6DE</gtr:id><gtr:impact>Successful grant application (Wellcome) and oral presentation at Biochemical Society meeting</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Developing ImageStream to quantify mitophagy</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2013</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Mice with fluorescent organelles for investigating mitophagy</gtr:description><gtr:id>8BD74746-4CBA-418A-977C-7FD14D15862E</gtr:id><gtr:impact>Liver stem cells with fluorescent organelles</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>RedMIT/GFP-LC3 mouse</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type><gtr:yearFirstProvided>2014</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>We developed a new method for studying the organisation of mtDNA in living cells using florescence microscopy. We can use this method diagnostically as a rapid screening method of patient-derived cultured cells. This is particularly useful posthumously, when a fibroblast cell line may be the only material available. Further work provided insights into the mode of action of and resistance to a major class of anti-cancer drugs (anthracylcines such as doxorubicin and daunorubicin). This may be very important for clinical oncology</gtr:description><gtr:id>38E256E6-805F-4D20-8A2F-83D9847550A1</gtr:id><gtr:impact>We have shown that a major class of anti-cancer drugs (anthracylcines such as doxorubicin and daunorubicin) can induce gross re-organisation of mtDNA packaging into nucleoids. These changes may contribute to the long term mtDNA damage and toxicity associated with the clinical use of these drugs</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Picogreen staining of mtDNA</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2008</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Human liver stem cell line obtained from Reneuron. Transformed with a tamoxifen controlled C-myc allows large quantiies of the cells to be produced before they are differentiated.</gtr:description><gtr:id>270D1614-EBBD-447F-85F3-D3F89782590E</gtr:id><gtr:impact>This line will hopefully provide us with a better system for looking at hepatocyte ischaemia reperfusion injury</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Human liver stem cell line</gtr:title><gtr:type>Cell line</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>In our mouse model of mild mitochondrial dysfunction and nutritional deprivation, we found that early exposure to the anti-AIDS drug AZT interacts with low protein diet to impair foetal development. This combination appeared to impair the supply of insulin and hence glucose homeostasis in the mouse, perhaps as a result of impaired mitochondrial function</gtr:description><gtr:id>883FDC91-7BE3-49A6-80FD-6CDA5B5F1020</gtr:id><gtr:impact>Maternal nutritional deprivation combined with AIDS therapy may influence both birth weight and onset of diabetes by effects on mitochondria. This has potential implications for management not only of type 2 diabetes but also for the AIDS pandemic</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Mouse model of mild mito dysfunction &amp; nutient deprivation</gtr:title><gtr:type>Model of mechanisms or symptoms - non-mammalian in vivo</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/14D69225-9B16-462B-A6A3-D5DC523084C4"><gtr:id>14D69225-9B16-462B-A6A3-D5DC523084C4</gtr:id><gtr:title>The mitochondrial DNA T16189C polymorphism and HIV-associated cardiomyopathy: a genotype-phenotype association study.</gtr:title><gtr:parentPublicationTitle>BMC medical genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/70390472be0fcc4daac0db706d21c0fb"><gtr:id>70390472be0fcc4daac0db706d21c0fb</gtr:id><gtr:otherNames>Shaboodien G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1471-2350</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D081DE49-1E3A-4310-9951-0EFF480B03B3"><gtr:id>D081DE49-1E3A-4310-9951-0EFF480B03B3</gtr:id><gtr:title>Adults with RRM2B-related mitochondrial disease have distinct clinical and molecular characteristics.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6459db0fb97de13ef30ce2614b06cb4a"><gtr:id>6459db0fb97de13ef30ce2614b06cb4a</gtr:id><gtr:otherNames>Pitceathly RD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/918F64F6-010D-4F33-A559-515AAB741E32"><gtr:id>918F64F6-010D-4F33-A559-515AAB741E32</gtr:id><gtr:title>Critical role of complex III in the early metabolic changes following myocardial infarction.</gtr:title><gtr:parentPublicationTitle>Cardiovascular research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/2aafcacfdc2b9b717a966c8e44df802e"><gtr:id>2aafcacfdc2b9b717a966c8e44df802e</gtr:id><gtr:otherNames>Heather LC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0008-6363</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6DBDB50B-DB2E-45BA-AB1B-32A32775A6D9"><gtr:id>6DBDB50B-DB2E-45BA-AB1B-32A32775A6D9</gtr:id><gtr:title>Buoyancy-Driven Continuous SPLITT Fractionation: A New Technique for Separation of Microspheres</gtr:title><gtr:parentPublicationTitle>Separation Science and Technology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/06c536426122298b838201a86566f7f2"><gtr:id>06c536426122298b838201a86566f7f2</gtr:id><gtr:otherNames>Storey J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5DFBF1D3-91B8-4AD6-B637-AE4B682BCB17"><gtr:id>5DFBF1D3-91B8-4AD6-B637-AE4B682BCB17</gtr:id><gtr:title>Diagnosis of mitochondrial DNA depletion syndromes.</gtr:title><gtr:parentPublicationTitle>Archives of disease in childhood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5e5ec211da0dca15b5656a9a543849cd"><gtr:id>5e5ec211da0dca15b5656a9a543849cd</gtr:id><gtr:otherNames>Rahman S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0003-9888</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/03E14F28-F068-4EF7-9D19-7A0224619B6F"><gtr:id>03E14F28-F068-4EF7-9D19-7A0224619B6F</gtr:id><gtr:title>Mosaicism for mitochondrial DNA polymorphic variants in placenta has implications for the feasibility of prenatal diagnosis in mtDNA diseases.</gtr:title><gtr:parentPublicationTitle>European journal of human genetics : EJHG</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6b6fdd7b4a52ccdc8ff80545d1f998d9"><gtr:id>6b6fdd7b4a52ccdc8ff80545d1f998d9</gtr:id><gtr:otherNames>Marchington DR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1018-4813</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D52E6E2E-542B-4749-8CF5-02B72566264F"><gtr:id>D52E6E2E-542B-4749-8CF5-02B72566264F</gtr:id><gtr:title>Collated mutations in mitochondrial DNA (mtDNA) depletion syndrome (excluding the mitochondrial gamma polymerase, POLG1).</gtr:title><gtr:parentPublicationTitle>Biochimica et biophysica acta</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d02cbf15604f6dbeb2eec035e333b499"><gtr:id>d02cbf15604f6dbeb2eec035e333b499</gtr:id><gtr:otherNames>Poulton J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0006-3002</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/18276E1E-B6FF-4420-8F2B-A4B6B80776BD"><gtr:id>18276E1E-B6FF-4420-8F2B-A4B6B80776BD</gtr:id><gtr:title>The effect of donor BMI on mitochondrial DNA copy number in isolated human pancreatic islets</gtr:title><gtr:parentPublicationTitle>XENOTRANSPLANTATION</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6fd9ed4bca2589914da7eb14615ea5de"><gtr:id>6fd9ed4bca2589914da7eb14615ea5de</gtr:id><gtr:otherNames>Walker Jonathan N.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0908-665X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/ACD2AF65-B977-40A3-90EC-A2CDF35521DC"><gtr:id>ACD2AF65-B977-40A3-90EC-A2CDF35521DC</gtr:id><gtr:title>Exome sequencing identifies ACAD9 mutations as a cause of complex I deficiency.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/35d3a74312ac86d45efc47ac78a3c98c"><gtr:id>35d3a74312ac86d45efc47ac78a3c98c</gtr:id><gtr:otherNames>Haack TB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/764CD766-28C5-4BA0-ABE1-E73F3FB20D74"><gtr:id>764CD766-28C5-4BA0-ABE1-E73F3FB20D74</gtr:id><gtr:title>Therapeutic treatments of mtDNA diseases at the earliest stages of human development.</gtr:title><gtr:parentPublicationTitle>Mitochondrion</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0a1b548c7be9d8e2dbb49a9dfa42719d"><gtr:id>0a1b548c7be9d8e2dbb49a9dfa42719d</gtr:id><gtr:otherNames>Chiaratti MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1567-7249</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/EA986B48-E556-4850-ACA2-EAAEA568D64E"><gtr:id>EA986B48-E556-4850-ACA2-EAAEA568D64E</gtr:id><gtr:title>Liver mtDNA content increases during development: a comparison of methods and the importance of age- and tissue-specific controls for the diagnosis of mtDNA depletion.</gtr:title><gtr:parentPublicationTitle>Mitochondrion</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d054c46e574e3ad48ce8fc847940e4a8"><gtr:id>d054c46e574e3ad48ce8fc847940e4a8</gtr:id><gtr:otherNames>Morten KJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1567-7249</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/4CA21B38-1257-4FE9-BB11-46717C002C83"><gtr:id>4CA21B38-1257-4FE9-BB11-46717C002C83</gtr:id><gtr:title>Mice expressing an error-prone DNA polymerase in mitochondria display elevated replication pausing and chromosomal breakage at fragile sites of mitochondrial DNA.</gtr:title><gtr:parentPublicationTitle>Nucleic acids research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/865382764ca1906d74eb953702268f34"><gtr:id>865382764ca1906d74eb953702268f34</gtr:id><gtr:otherNames>Bailey LJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0305-1048</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/08C09522-3941-46F3-9FDA-D837FA10E2FA"><gtr:id>08C09522-3941-46F3-9FDA-D837FA10E2FA</gtr:id><gtr:title>Loss of autophagy in erythroid cells leads to defective removal of mitochondria and severe anemia in vivo.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/30373c619109bc39028647979ba3b159"><gtr:id>30373c619109bc39028647979ba3b159</gtr:id><gtr:otherNames>Mortensen M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/654C6F7B-01B1-40CE-9167-14C6FCAC6B08"><gtr:id>654C6F7B-01B1-40CE-9167-14C6FCAC6B08</gtr:id><gtr:title>Information for genetic management of mtDNA disease: sampling pathogenic mtDNA mutants in the human germline and in placenta.</gtr:title><gtr:parentPublicationTitle>Journal of medical genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d8a455c86c9167373d3df1fc91c0f565"><gtr:id>d8a455c86c9167373d3df1fc91c0f565</gtr:id><gtr:otherNames>Marchington D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-2593</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7168F4E3-9414-4CE4-9B98-DDBAD1D2C1E5"><gtr:id>7168F4E3-9414-4CE4-9B98-DDBAD1D2C1E5</gtr:id><gtr:title>Cultured muscle cells display defects of mitochondrial myopathy ameliorated by anti-oxidants.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/089c973b7dc9df4114fe01a5f3ed5bb9"><gtr:id>089c973b7dc9df4114fe01a5f3ed5bb9</gtr:id><gtr:otherNames>Vergani L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/075DDE31-9F3B-4070-91BB-6155BF588955"><gtr:id>075DDE31-9F3B-4070-91BB-6155BF588955</gtr:id><gtr:title>Insights into pancreatic ? cell energy metabolism using rodent ? cell models</gtr:title><gtr:parentPublicationTitle>Wellcome Open Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1ebfff718292be8266cc333e87e7c9b3"><gtr:id>1ebfff718292be8266cc333e87e7c9b3</gtr:id><gtr:otherNames>Morten K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/BE892E12-0C6B-4EEB-AA6F-B1183C647B3E"><gtr:id>BE892E12-0C6B-4EEB-AA6F-B1183C647B3E</gtr:id><gtr:title>RRM2B mutations are frequent in familial PEO with multiple mtDNA deletions.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f950fd99d3923d0e32eb2c63f89184e9"><gtr:id>f950fd99d3923d0e32eb2c63f89184e9</gtr:id><gtr:otherNames>Fratter C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C9F6977F-B25D-4E5D-8FB4-6833F82BCA1A"><gtr:id>C9F6977F-B25D-4E5D-8FB4-6833F82BCA1A</gtr:id><gtr:title>Genetic causes of mitochondrial DNA depletion in humans.</gtr:title><gtr:parentPublicationTitle>Biochimica et biophysica acta</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/231935976250c8c8994531c043c1de62"><gtr:id>231935976250c8c8994531c043c1de62</gtr:id><gtr:otherNames>R?tig A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0006-3002</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A83097A0-8110-48A9-97AA-E0E451C8EFAA"><gtr:id>A83097A0-8110-48A9-97AA-E0E451C8EFAA</gtr:id><gtr:title>Reversible infantile respiratory chain deficiency is a unique, genetically heterogenous mitochondrial disease.</gtr:title><gtr:parentPublicationTitle>Journal of medical genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/cffc962b932447a7204bc4603ea0b0cd"><gtr:id>cffc962b932447a7204bc4603ea0b0cd</gtr:id><gtr:otherNames>Uusimaa J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-2593</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/698A1202-1410-4DB8-875D-CE898BD54E7F"><gtr:id>698A1202-1410-4DB8-875D-CE898BD54E7F</gtr:id><gtr:title>174th ENMC international workshop: Applying pre-implantation genetic diagnosis to mtDNA diseases: implications of scientific advances 19-21 March 2010, Naarden, The Netherlands.</gtr:title><gtr:parentPublicationTitle>Neuromuscular disorders : NMD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d02cbf15604f6dbeb2eec035e333b499"><gtr:id>d02cbf15604f6dbeb2eec035e333b499</gtr:id><gtr:otherNames>Poulton J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0960-8966</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D7FEA51C-4158-481E-A1BC-551C697D303E"><gtr:id>D7FEA51C-4158-481E-A1BC-551C697D303E</gtr:id><gtr:title>Preventing transmission of maternally inherited mitochondrial DNA diseases.</gtr:title><gtr:parentPublicationTitle>BMJ (Clinical research ed.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d02cbf15604f6dbeb2eec035e333b499"><gtr:id>d02cbf15604f6dbeb2eec035e333b499</gtr:id><gtr:otherNames>Poulton J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0959-535X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/356B7148-C8B5-484E-BB61-D3C5CE98AD22"><gtr:id>356B7148-C8B5-484E-BB61-D3C5CE98AD22</gtr:id><gtr:title>Anticancer DNA intercalators cause p53-dependent mitochondrial DNA nucleoid re-modelling.</gtr:title><gtr:parentPublicationTitle>Oncogene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0eb385c284028d5bbe25637a9786b922"><gtr:id>0eb385c284028d5bbe25637a9786b922</gtr:id><gtr:otherNames>Ashley N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0950-9232</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5FB14F29-9176-4CFF-B430-233426CB8F3A"><gtr:id>5FB14F29-9176-4CFF-B430-233426CB8F3A</gtr:id><gtr:title>Mitochondrial DNA is a direct target of anti-cancer anthracycline drugs.</gtr:title><gtr:parentPublicationTitle>Biochemical and biophysical research communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0eb385c284028d5bbe25637a9786b922"><gtr:id>0eb385c284028d5bbe25637a9786b922</gtr:id><gtr:otherNames>Ashley N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0006-291X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0B10B626-938E-4C1A-BCC2-2954FB0A3817"><gtr:id>0B10B626-938E-4C1A-BCC2-2954FB0A3817</gtr:id><gtr:title>Depletion of mitochondrial DNA in fibroblast cultures from patients with POLG1 mutations is a consequence of catalytic mutations.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0eb385c284028d5bbe25637a9786b922"><gtr:id>0eb385c284028d5bbe25637a9786b922</gtr:id><gtr:otherNames>Ashley N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/93A0D442-A9AF-462B-9345-3F940748B956"><gtr:id>93A0D442-A9AF-462B-9345-3F940748B956</gtr:id><gtr:title>Detailed analysis of variation at and around mitochondrial position 16189 in a large Finnish cohort reveals no significant associations with early growth or metabolic phenotypes at age 31 years.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical endocrinology and metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4a504a56bb9fa233e44d7ee8566f2030"><gtr:id>4a504a56bb9fa233e44d7ee8566f2030</gtr:id><gtr:otherNames>Das S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0021-972X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/4446864B-4E3C-4C96-AA44-197CBAA5B24B"><gtr:id>4446864B-4E3C-4C96-AA44-197CBAA5B24B</gtr:id><gtr:title>Transmission of mitochondrial DNA diseases and ways to prevent them.</gtr:title><gtr:parentPublicationTitle>PLoS genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d02cbf15604f6dbeb2eec035e333b499"><gtr:id>d02cbf15604f6dbeb2eec035e333b499</gtr:id><gtr:otherNames>Poulton J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1553-7390</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E303C307-A5C0-480B-A026-54E06FF1BE79"><gtr:id>E303C307-A5C0-480B-A026-54E06FF1BE79</gtr:id><gtr:title>Defects in maintenance of mitochondrial DNA are associated with intramitochondrial nucleotide imbalances.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0eb385c284028d5bbe25637a9786b922"><gtr:id>0eb385c284028d5bbe25637a9786b922</gtr:id><gtr:otherNames>Ashley N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/94168B05-9E3F-4177-9C08-925976FC10BE"><gtr:id>94168B05-9E3F-4177-9C08-925976FC10BE</gtr:id><gtr:title>163rd ENMC International Workshop: nucleoid and nucleotide biology in syndromes of mitochondrial DNA depletion myopathy 12-14 December 2008, Naarden, The Netherlands.</gtr:title><gtr:parentPublicationTitle>Neuromuscular disorders : NMD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d02cbf15604f6dbeb2eec035e333b499"><gtr:id>d02cbf15604f6dbeb2eec035e333b499</gtr:id><gtr:otherNames>Poulton J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0960-8966</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8704B11B-AECB-498E-A8F0-E3848F1FF707"><gtr:id>8704B11B-AECB-498E-A8F0-E3848F1FF707</gtr:id><gtr:title>The clinical, histochemical, and molecular spectrum of PEO1 (Twinkle)-linked adPEO.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f950fd99d3923d0e32eb2c63f89184e9"><gtr:id>f950fd99d3923d0e32eb2c63f89184e9</gtr:id><gtr:otherNames>Fratter C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0500695</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>160D22D0-5677-4513-A0AC-7F3526B7F336</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Metabolic and Endocrine</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>